Showing results (401-410 of 447) with videos related to

Sort By:
Pageof 45
Biorxiv : the Preprint Server for Biology|July 1, 2024
TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replicationMaria Gonzalez-Orozco, Hsiang-Chi Tseng, Adam Hage, et al.
Oncotarget|May 15, 2018
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastasesLeticia De Mattos-Arruda, Charlotte K Y Ng, Salvatore Piscuoglio, et al.
Journal of Proteome Research|July 10, 2015
In Vitro Transcription/Translation System: A Versatile Tool in the Search for Missing ProteinsPéter Horvatovich, Ákos Végvári, Justin Saul, et al.
The Lancet. Oncology|April 2, 2026
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trialVanesa Gregorc, Margarita Majem, Giuseppe Lo Russo, et al.
Clinical Kidney Journal|October 29, 2014
Renal replacement therapy in Latin American end-stage renal diseaseGuillermo Rosa-Diez, Maria Gonzalez-Bedat, Roberto Pecoits-Filho, et al.
Nature Communications|February 24, 2025
Artificial intelligence for modeling and understanding extreme weather and climate eventsGustau Camps-Valls, Miguel-Ángel Fernández-Torres, Kai-Hendrik Cohrs, et al.
Cancer Research|May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 21, 2025
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registryMaria Gonzalez-Cao, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, et al.
Plos One|April 16, 2015
Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 StudyIván Márquez-Rodas, Manuel Martín González, Eduardo Nagore, et al.
Breast Cancer Research : BCR|July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationYan Xing, Nancy U Lin, Matthew A Maurer, et al.
Pageof 45